癌症对后续妊娠机会的影响:一项基于人群的分析
该回顾性队列研究纳入苏格兰1981至2012年间确诊癌症的39岁及以下女性共23201例,分析其后续妊娠情况。癌症幸存者妊娠率降低(标化发病比0.62,95%CI:0.60,0.63),首次妊娠机会也较低(调整风险比0.57,95%CI:0.53,0.61)。
要点
- 所有癌症类型的幸存者妊娠率均降低,标化发病比为0.62(95%CI:0.60,0.63)。
- 确诊后超过5年首次妊娠的调整风险比为0.57(95%CI:0.53,0.61)。
- 乳腺癌、宫颈癌、脑/中枢神经系统肿瘤及白血病患者的妊娠机会下降明显。
核心结论
- 癌症幸存者所有癌症类型的妊娠数均减少,首次妊娠机会也较低。
- 近期治疗年代整体及宫颈癌、乳腺癌、霍奇金淋巴瘤中效应减弱,但白血病或脑/中枢神经系统肿瘤无变化。
- 癌症诊断后以终止妊娠结束的比例较低,以活产结束的比例较高(78.7% vs 75.6%,差值CI:1.1,5.0)。
研究设计与样本
- 回顾性队列研究,关联1981至2012年苏格兰癌症登记与医院出院记录,纳入诊断时年龄≤39岁的女性23201例,妊娠随访至2014年底。
- 暴露组中诊断前未妊娠的女性10271例与按年龄、贫困五分位和诊断年份匹配的普通人群对照比较。
主要发现
- 癌症幸存者妊娠标化发病比为0.62(95%CI:0.60,0.63),所有癌症类型均观察到降低。
- 诊断后超过5年首次妊娠的调整风险比为0.57(95%CI:0.53,0.61),乳腺癌、宫颈癌、脑/中枢神经系统肿瘤和白血病中下降明显。
- 癌症诊断后妊娠以终止妊娠结束的比例较低,以活产结束的比例较高(78.7% vs 75.6%,差值CI:1.1,5.0)。
临床怎么用
- 作者认为,所有癌症类型妊娠机会降低以及部分常见癌症影响变化的证据,凸显了在诊断时对所有育龄女性进行适当生育咨询的必要性。
局限性
- 未获得所接受治疗的详细信息,因此无法评估具体治疗方案对生育力的影响。
- 最近时间段诊断的女性随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the impact of cancer in females aged ≤39 years on subsequent chance of pregnancy? SUMMARY ANSWER: Cancer survivors achieved fewer pregnancies across all cancer types, and the chance of achieving a first pregnancy was also lower. WHAT IS KNOWN ALREADY: The diagnosis and treatment of cancer in young females may be associated with reduced fertility but the true pregnancy deficit in a population is unknown. STUDY DESIGN, SIZE, DURATION: We performed a retrospective cohort study relating first incident cancer diagnosed between 1981 and 2012 to subsequent pregnancy in all female patients in Scotland aged 39 years or less at cancer diagnosis (n = 23 201). Pregnancies were included up to end of 2014. Females from the exposed group not pregnant before cancer diagnosis (n = 10 271) were compared with general population controls matched for age, deprivation quintile and year of diagnosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Scottish Cancer Registry records were linked to hospital discharge records to calculate standardized incidence ratios (SIR) for pregnancy, standardized for age and year of diagnosis. Linkage to death records was also performed. We also selected women from the exposed group who had not been pregnant prior to their cancer diagnosis who were compared with a matched control group from the general population. Additional analyses were performed for breast cancer, Hodgkin lymphoma, leukaemia, cervical cancer and brain/CNS cancers. MAIN RESULTS AND THE ROLE OF CHANCE: Cancer survivors achieved fewer pregnancies: SIR 0.62 (95% CI: 0.60, 0.63). Reduced SIR was observed for all cancer types. The chance of achieving a first pregnancy was also lower, adjusted hazard ratio = 0.57 (95% CI: 0.53, 0.61) for women >5 years after diagnosis, with marked reductions in women with breast, cervical and brain/CNS tumours, and leukaemia. The effect was reduced with more recent treatment period overall and in cervical cancer, breast cancer and Hodgkin lymphoma, but was unchanged for leukaemia or brain/CNS cancers. The proportion of pregnancies that ended in termination was lower after a cancer diagnosis, and the proportion ending in live birth was higher (78.7 vs 75.6%, CI of difference: 1.1, 5.0). LIMITATIONS, REASONS FOR CAUTION: Details of treatments received were not available, so the impact of specific treatment regimens on fertility could not be assessed. Limited duration of follow-up was available for women diagnosed in the most recent time period. WIDER IMPLICATIONS OF THE FINDINGS: This analysis provides population-based quantification by cancer type of the effect of cancer and its treatment on subsequent pregnancy across the reproductive age range, and how this has changed in recent decades. The demonstration of a reduced chance of pregnancy across all cancer types and the changing impact in some but not other common cancers highlights the need for appropriate fertility counselling of all females of reproductive age at diagnosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by NHS Lothian Cancer and Leukaemia Endowments Fund. Part of this work was undertaken in the MRC Centre for Reproductive Health which is funded by the MRC Centre grant MR/N022556/1. RAA has participated in Advisory Boards and/or received speaker's fees from Beckman Coulter, IBSA, Merck and Roche Diagnostics. He has received research support from Roche Diagnostics, Ansh labs and Ferring. The other authors have no conflicts to declare.
引用
- Anderson RA, Brewster DH, Wood R, et al. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. Hum Reprod. 2018. PMID: 29912328. doi:10.1093/humrep/dey216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。